Enara Bio Company
Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the вАЬimmune synapseвАЭ) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-related DNA sequences.
Headquarters:
London, England, United Kingdom
Last Funding Type:
Series A
Investors Number:
2
Last Funding Date:
2019-11-06
Employee Number:
11-50
Total Funding:
17500000
Founded Date:
2016-01-01
Estimated Revenue:
$1M to $10M
Industry:
Tumor-Specific Antigens
Funding Status:
Early Stage Venture